The Distribution of Metastatic Renal Cell Carcinoma by Presenting Tumor Stage in the Modern Era

Sharp, Evan; Guduru, Anirudh; May, Allison; Lombardo, Lindsay; Siddiqui, Sameer; Hamilton, Zachary

doi:10.1016/j.clgc.2022.03.001

Cited by 3 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Sharp et al showed a stage migration to metastatic RCC for a higher proportion of patients presenting with cT1-2 disease, as opposed to cT3-4. Additionally, they observed that there is a possible increase in cT1 tumors with metastatic potential, presenting in 1 in 4 metastatic patients [ 25 ]. However, even in our series, the primary tumor AJCC stage remains one of the most essential predictors of oncological outcomes, guiding the selection of the best treatment choice for patients with RCC.…”

Section: Discussionmentioning

confidence: 99%

The Impact of Metastasectomy on Survival Outcomes of Renal Cell Carcinoma: A 10-Year Single Center Experience

Ferriero

Cacciatore

Ochoa

et al. 2023

Cancers

View full text Add to dashboard Cite

Objectives: The role of surgical metastasectomy (MST) in solitary or oligometastasis from renal cell carcinoma (RCC) and its impact on survival outcomes remains poorly addressed. We evaluated the impact of MST on overall survival (OS) in patients with oligometastatic (m)RCC. Materials and methods: The institutional renal cancer prospective database was examined for cases treated with partial or radical nephrectomy who developed metastatic disease during follow-up. Patients with evidence of clinical metastasis at first diagnosis were excluded. Patients considered unfit for MST received systemic treatment (ST); all others received MST. The impact of MST vs. the ST only cohort was assessed with the Kaplan–Meier method. Age, gender, bilaterality, histology, AJCC stage of primary tumor, surgical margins, local vs. distant metastasis and MST were included in univariable and multivariable regression analyses to assess the predictors of OS. Results: Overall, at a median follow-up of 16 months after primary treatment, 168 patients with RCC developed asynchronous metastasis at the adrenal gland, lung, liver, spleen, peritoneal, renal fossa, bone, nodes, brain and thyroid gland. Nine patients unfit for any treatment were excluded. The site of metastasis was treated with surgical MST (77/159, 48.4%), with or without previous or subsequent ST, while 82/159 cases (51.2%) received ST only. The 2-year, 5-year and 10-year OS probabilities were 93.8%, 82.8% and 79.5%, respectively. After multivariable analysis, MST and the primary tumor AJCC stage were independent predictors of OS probabilities (p = 0.019 and p = 0.035, respectively). After Kaplan–Meier analysis, MST significantly improved OS probabilities versus patients receiving ST (p < 0.001). Limitations: The main drawbacks of our research were the small sample size from a single-tertiary referral institution, as well as the absent or different ST lines in the cohort of patients receiving MST. Conclusions: When an NED status is achievable, surgical MST of mRCC significantly impacts OS, delaying and not precluding further subsequent ST.

show abstract

Section: Discussionmentioning

confidence: 99%

The Impact of Metastasectomy on Survival Outcomes of Renal Cell Carcinoma: A 10-Year Single Center Experience

Ferriero

Cacciatore

Ochoa

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…With the increased use of cross-sectional imaging, incidental renal masses are being diagnosed at an increasing frequency, among older patients, and at smaller sizes [1] , [2] . Many of these masses are indolent, and a growing body of evidence supports the long-term safety of active surveillance for appropriately selected renal mass patients [3] , [4] .…”

Section: Introductionmentioning

confidence: 99%

The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype

Monda

Lui

Pratsinis

et al. 2023

European Urology Open Science

View full text Add to dashboard Cite

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro

Tsaur

Thomas

Taşkıran

et al. 2022

Cancers

View full text Add to dashboard Cite

Chronic treatment of renal cell carcinoma (RCC) with the tyrosine kinase inhibitor sunitinib (ST) inevitably induces resistance and tumor re-activation. This study investigated whether adding the natural compound sulforaphane (SFN) with its anti-cancer properties could improve ST efficacy in vitro. The RCC cell lines A498, Caki1, KTCTL26, and 786O were exposed to ST, SFN, or both (dual therapy, DT) before (short-term exposure) and during ST-resistance buildup (long-term 8-week exposure). Tumor growth, proliferation, and clone formation were evaluated, as was cell cycle progression and cell cycle regulating proteins. In nonresistant cells (short-term), DT induced a higher reduction in cell viability in three cell lines as compared to monotherapy with either ST or SFN. Long-term SFN or DT significantly reduced tumor growth and proliferation, whereas ST alone had no effect or even elevated proliferation in three cell lines. SFN or DT (but not ST alone) also blocked clonogenic growth. Both long-term SFN and DT enhanced the number of cells in the S- and/or G2/M-phase. Protein analysis in 786O cells revealed a down-regulation of cyclin dependent kinase (CDK) 1 and 2. CDK2 or Cyclin A knockdown caused reduced 786O growth activity. SFN therefore inhibits or delays resistance to chronic ST treatment.

show abstract

The Distribution of Metastatic Renal Cell Carcinoma by Presenting Tumor Stage in the Modern Era

Cited by 3 publications

References 14 publications

The Impact of Metastasectomy on Survival Outcomes of Renal Cell Carcinoma: A 10-Year Single Center Experience

The Impact of Metastasectomy on Survival Outcomes of Renal Cell Carcinoma: A 10-Year Single Center Experience

The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro

Contact Info

Product

Resources

About